Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019 Background After a loading dose of ticagrelor, the rate of high on‐treatment platelet reactivity remains elevated, which increases periprocedural myocardial infarction and injury.
Moazez J. Marian +11 more
doaj +1 more source
Recreation of the terminal events in physiological integrin activation. [PDF]
, 2010 Increased affinity of integrins for the extracellular matrix (activation) regulates cell adhesion and migration, extracellular matrix assembly, and mechanotransduction.
Bobkov, Andrey A +8 more
core +3 more sources
BMC Cardiovascular Disorders, 2002 Background GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Giusti Andrea, Bertuglia Silva
doaj +1 more source
Abciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopenia [PDF]
, 2006 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90080/1/phco.26.3.423 ...
Dorsch, Michael P. +3 more
core +1 more source
Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice [PDF]
, 2019 We investigated the contribution of human platelets to macrophage effector properties in the presence of lipopolysaccharide (LPS), as well as the beneficial effects and time frame for platelet transfusion in septic animals.
Carestia, Agostina +9 more
core +1 more source
Stroke in Patients With Acute Coronary Syndromes: Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial [PDF]
, 1999 BACKGROUND: The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates.
Alberts, M.J. +14 more
core +1 more source
Journal of Clinical and Preventive Cardiology, 2021 Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen and adhesion proteins such as fibronectin, vitronectin, and von Willebrand ...
Savvy Nandal +2 more
doaj +1 more source
Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome [PDF]
, 2006 The purpose of this study is to explain the rationale for the value of information approach to priority setting for research and to describe the methods intuitively for those familiar with basic decision analytical modeling.
Bojke, L. +4 more
core +1 more source
A rare case of eptifibatide-induced thrombocytopenia
Journal of Community Hospital Internal Medicine Perspectives, 2021 Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar +4 more
doaj +1 more source
Structural basis for pure antagonism of integrin αVβ3 by a high affinity form of fibronectin [PDF]
, 2014 Integrins are important therapeutic targets. However, current RGD-based anti-integrin drugs are also partial agonists, inducing conformational changes that trigger potentially fatal immune reactions and paradoxical cell adhesion.
Adair, Brian D. +6 more
core +1 more source